ANI Pharmaceuticals's revenue per share for the
three
months ended in Mar. 2024 was $7.08.
ANI Pharmaceuticals's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $27.32.
During the past 12 months, the average Revenue Per Share Growth Rate of ANI Pharmaceuticals was 24.70% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 15.40% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 7.70% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 16.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for ANI Pharmaceuticals's Revenue per Share or its related term are showing as below:
ANIP'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -74.3 Med: 19.45 Max: 385
Current: 15.4
During the past 13 years, ANI Pharmaceuticals's highest 3-Year average Revenue Per Share Growth Rate was 385.00% per year. The lowest was -74.30% per year. And the median was 19.45% per year.
ANIP's 3-Year Revenue Growth Rate is ranked better than 76.63% of 920
companies
in the Drug Manufacturers industry
Industry Median: 6.4
vs ANIP: 15.40
ANI Pharmaceuticals Revenue per Share Historical Data
The historical data trend for ANI Pharmaceuticals's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ANI Pharmaceuticals's Revenue per Share
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's PS Ratio falls into.
ANI Pharmaceuticals Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
ANI Pharmaceuticals's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (NAS:ANIP) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
ANI Pharmaceuticals Revenue per Share Related Terms
Thank you for viewing the detailed overview of ANI Pharmaceuticals's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
ANI Pharmaceuticals (ANI Pharmaceuticals) Business Description
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANIP has been successfully added to your 